Retatrutide is being developed by Eli Lilly and is currently described by the company as an investigational once-weekly triple hormone receptor agonist
When to seek urgent care: Severe or persistent nausea and vomiting leading to dehydration contact NHS 111 or your trial team Sudden, severe abdominal pain seek urgent medical attention Signs of a severe allergic reaction (anaphylaxis), including rash, swelling of the face, lips, or throat, or difficulty breathing call 999 immediately Upper right abdominal pain, fever, or jaundice seek medical attention Any new or worsening symptoms following an injection contact your trial team Reporting side effects: Patients and healthcare professionals are encouraged to report suspected adverse reactions via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app
STEP 1 Fill out a short form and connect with a licensed medical professional 100% online
The gradual dose titration recommended in product SmPCs helps minimise gastrointestinal intolerance
Generic or unverifiable certificates of analysis
The injectable form typically delivers more consistent results because injection bypasses the digestive system, where stomach acid and food can reduce drug bioavailability
